Apoptosis and osteoporosis

American Journal of Medicine

Volumn 108, Issue 2, 2000, Pages 153-164

  Weinstein, Robert S ^a   Manolagas, Stavros C ^a  

^a Department of Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

APOPTOSIS; BONE MASS; BONE MINERAL; BONE REMODELING; BONE TURNOVER; ESTROGEN DEFICIENCY; HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0033978735     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00420-9     Document Type: Article

References (60)

1. Hoffbrand AV, Lewis SM. Postgraduate Hematology, 3rd ed. Oxford: Butterworth-Heinemann, Ltd, 1992:7.
2. Frost H.M. Tetracycline bone labeling in anatomy. Am J Phys Anthropol. 29:1968;183-196.
3. Parfitt A.M., Mathews C., Rao D., et al. Impaired osteoblast function in metabolic bone disease. DeLuca H.F., Frost H., Jee W., Johnston C., Parfitt A.M. Osteoporosis Recent Advances in Pathogenesis and Treatment . 1981;321-330 University Park Press, Baltimore.
4. Parfitt A.M. Osteoclast precursors as leukocytes importance of the area code . Bone. 23:1998;491-494.
5. Parfitt A.M. Osteonal and hemi-osteonal remodeling the spatial and temporal framework for signal traffic in adult human bone . J Cell Biochem. 55:1994;273-286.
6. Triffitt J.T. The stem cell of the osteoblast. Bilezikian J.P., Raisz L.G., Rodan G.A. Principles of Bone Biology. 1996;39-50 Academic Press, San Diego.
7. Manolagas S.C., Jilka R.L. Bone marrow, cytokines, and bone remodeling emerging insights into the pathophysiology of osteoporosis . NEJM. 332:1995;305-311.
8. Abe E, Yamamoto M, Taguchi Y, et al. Requirement of BMPs2/4 for postnatal osteoblast and osteoclast formation: antagonism by noggin. J Bone Miner Res (in press).
9. Ducy P., Zhang R., Geoffroy V., et al. Osf2/Cbfa1 a transcriptional activator of osteoblast differentiation . Cell. 89:1997;747-754.
10. Corral D.A., Amling M., Priemel M., et al. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci USA. 95:1998;13835-13840.
11. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
12. Boyle W.J., Kung Y., Lacey D.L., et al. Osteoprotegerin ligand is required for murine osteoclastogenesis. Bone. 23:1998;S189.
13. O'Brien C.A., Farrar N.C., Manolagas S.C. Identification of an OSF-2 binding site in the murine RANKL/OPGL gene promoter a potential link between osteoblastogenesis and osteoclastogenesis . Bone. 23:1998;S149.
14. Baron R., Vignery A., Horowitz. Lymphocytes, macrophages and the regulation of bone remodeling. Peck W.A. Bone and Mineral Research, Annual 2. 1984;175-243 Elsevier, Amsterdam.
15. Hughes D.E., Boyce B.F. Apoptosis in bone physiology and disease. J Clin Pathol Mol Pathol. 50:1997;132-137.
16. Parfitt A.M. Bone-forming cells in clinical conditions. Hall B.K. Bone Volume 1, The Osteoblast and Osteocyte . 1992;351-429 CRC Press, Boca Raton.
17. Jilka R.L., Weinstein R.S., Bellido T., et al. Osteoblast programmed cell death (apoptosis) modulation by growth factors and cytokines . J Bone Miner Res. 13:1998;793-802.
18. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids potential mechanisms of the deleterious effects on bone . J Clin Invest. 102:1998;274-282.
19. Friedmann I. Gross anatomy and development. In: Pathology of the Ear. Oxford: Blackwell, 1974:9.
20. Frost H.M. In vivo osteocyte death. J Bone Joint Surg [Am]. 42:1960;138-143.
21. Dunstan C.R., Evans R.A., Hills E., et al. Bone death in hip fracture in the elderly. Calcif Tissue Int. 47:1990;270-275.
22. Bason W.E. Secular trends in hip fracture occurrence and survival; age and sex differences. J Aging Heath. 8:1996;538-553.
23. Jilka R.L. Cytokines, bone remodeling, and estrogen deficiency a 1998 update . Bone. 23:1998;75-81.
24. Weinstein R.S., Majumdar S. Fractal geometry and vertebral compression fractures. J Bone Miner Res. 9:1994;1797-1802.
25. Hughes D.E., Dai A., Tiffee J.C., et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β Nature Med. 2:1996;1132-1136.
26. Kameda T., Mano H., Yuasa T., et al. Estrogen inhibits bone resorption by directly inducing apoptosis of bone-resorbing osteoclasts. J Exp Med. 186:1997;489-495.
27. Raisz L.G. Estrogen and bone new pieces to the puzzle . Nature Med. 2:1996;1077-1078.
28. Tomkinson A., Reeve J., Shaw R.W., Noble B.S. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab. 82:1997;3128-3135.
29. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. The effect of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblast lineage. Endocrinology. 138:1997;4013-4021.
30. Snapper I. Osteoporosis. In: Bone Disease in Medical Practice. New York: Grune & Stratton, 1957:21-22.
31. Zuckerman J.D. Hip fracture. NEJM. 334:1996;1519-1525.
32. Prestwood K.M., Pilbeam C.C., Burleson J.A., et al. The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab. 79:1994;366-371.
33. Albright F, Reifenstein EC. Metabolic bone disease: osteoporosis. In: The Parathyroid Glands and Metabolic Bone Disease: Selected Studies. Baltimore: Williams and Wilkins, 1948:162.
34. Weinstein R.S., Hutson M.S. Decreased trabecular width and increased trabecular spacing contribute to the bone loss with aging. Bone. 8:1987;137-142.
35. Jilka R.L., Weinstein R.S., Takahashi K., et al. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest. 97:1996;1732-1740.
36. Lips P., Courpron P., Meunier P.J. Mean wall thickness of trabecular bone packets in the human iliac crest changes with age . Calcif Tiss Res. 26:1978;13-17.
37. Darby A.J., Meunier P.J. Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calci Tissue Int. 33:1981;199-204.
38. Meunier P., Aaron J., Edouard C., Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. Clin Orthop. 80:1971;147-154.
39. Lips P., Van Ginkel F.C., Netelenbos J.C. Bone marrow and bone remodeling. Bone. 6:1985;343-344.
40. Burkhardt R., Kettner G., Böhm W., et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age a comparative histomorphometric study . Bone. 8:1987;157-164.
41. Lecka-Czernik B, Gubrij I, Moerman EA, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-gamma 2. J Cell Biochem 1999;74:357-371.
42. Dunstan C.R., Somers N.M., Evans R.A. Osteocyte death and hip fracture. Calcif Tissue Int. 53:1993;S113-S117.
43. Noble B.S., Stevens H., Loveridge N., Reeve J. Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone. 20:1997;273-282.
44. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp. 50:1932;137-195.
45. Fitzpatrick L.A. Glucocorticoid-induced osteoporosis. Marcus R. Osteoporosis. 1994;202-226 Blackwell, Boston.
46. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids potential mechanism of their deleterious effects on bone . J Clin Invest. 102:1998;274-282.
47. Mankin H.J. Nontraumatic necrosis of bone (osteonecrosis). NEJM. 326:1992;1473-1479.
48. Centrella M., Rosen V., Wozney J.M., et al. Opposing effects by glucocorticoids and bone morphogenic protein-2 in fetal rat bone cell cultures. J Cell Biochem. 67:1997;528-540.
49. Chang D.J., Ji C., Kin K.K., et al. Reduction in transforming growth factor beta receptor I expression and transcription factor Cbfa1 on bone cells by glucocorticoids. J Biol Chem. 273:1998;4892-4896.
50. Shi X.M., Chang Z.J., Blair H.C., et al. Glucocorticoids induce adipogenesis of stromal cells by transcriptionally activating PPARγ2. J Bone Miner Res. 12:1998;S454.
51. Weinstein R.S., Nicholas R.W., Kirchner J.R., et al. Anatomic juxtaposition of apoptotic osteocytes and avascular necrosis in femurs from patients with glucocorticoid excess. Bone. 23:1998;S461.
52. Felson D.T., Anderson J.J. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet. i:1987;902-905.
53. Luckman S.P., Coxon F.P., Ebetino F.H., et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation evidence from structure-activity relationships in J774 macrophages . J Bone Miner Res. 13:1998;1668-1678.
54. McClung M., Clemmesen B., Daifotis A., et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med. 128:1998;253-261.
55. Bone H.G., Downs R.W., Tucci J.R., et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab. 82:1997;265-274.
56. Reid I.R., Nicholson G.C., Weinstein R.S., et al. Alendronate in Paget's disease. Am J Med. 101:1996;341-348.
57. Dempster D.W., Cosman F., Parisien M., et al. Anabolic actions of parathyroid hormone on bone. Endocrine Rev. 14:1993;690-709.
58. Jilka R.L., Weinstein R.S., Roberson P., et al. PTH increases bone formation by postponing osteoblast apoptosis, not by increasing precursor proliferation. Bone. 23:1998;S519.
59. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363-1374.
60. Hirano T., Burr D.B., Turner C., et al. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res. 14:1999;536-545.